Ignite Creation Date:
2024-05-06 @ 5:43 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05408845
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2022-06-02
Brief Title:
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment Chemotherapy With Docetaxel Plus Trastuzumab for Recurrent Metastatic or Unresectable HER2-Positive Salivary Gland Cancer
Sponsor:
NRG Oncology
Organization:
NRG Oncology
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-30
Start Date Type:
ACTUAL
Primary Completion Date:
2028-07-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-07-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-02
First Submit QC Date:
June 2 2022
Study First Post Date:
2022-06-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-05
Last Update Post Date:
2024-02-07
Last Update Post Date Type:
ACTUAL